UNSPSC 51433101: Enalkiren

This classification denotes an antihypertensive agent with the molecular formula C35H56N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0U7YZ42Z47, chemically known as l-histidinamide, n-(3-amino-3-methyl-1-oxobutyl)-o-methyl-l-tyrosyl-n-(1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-, (1s-(1r*,2s*,3r*))- but generally known as enalkiren, which bears US NIH Compound Identifier 60594. European Medicines Agency schedules Enalkiren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06516MIG.

UNSPSC 51433101 Enalkiren, a Commodity code, reflects state and local procurement for emergency and critical-care medications supplied to fire rescue, EMS, and public health programs. The work encompasses acquiring pharmaceutical products — typically in bulk unit quantities — that meet stringent expiration and quality standards, with vendors responsible for product sourcing, regulatory compliance documentation (Safety Data Sheets, FDA certification, Good Manufacturing Practices attestation), cold-chain or standard logistics, and often pickup and replacement of expired stock before contract terms end. Issuing bodies include city purchasing departments (Tampa Fire Rescue through the City of Tampa), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). The code sees activity across municipal emergency services procurement, state pharmacy benefit and therapeutic initiatives, and shared purchasing vehicles that aggregate demand across jurisdictions to negotiate manufacturer and wholesaler pricing.

Recent activity spans Florida, Texas, and the Upper Midwest through multistate cooperative agreements. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026 for Advanced Life Support Medications — 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials — with bids due April 8, 2026, an estimated contract value of $40,000, a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount (not to exceed $10,000), and a one-year term with two optional one-year renewals. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting, net pricing models, and outcomes-based agreements outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement issued an RFP through MMCAP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026, a two-year term, and a 3 percent administrative fee requirement.